
Under hub-and-spoke biotech, serial founders launch new startup hoping to make gene therapies for the eye
In late July, Sangamo’s former R&D chief Adrian Woolfson, who left the biotech when it split its R&D, launched his own gene therapy outfit. Replay’s primary platform was an HSV vector which, as a hub-and-spoke biotech, it said it was building four different companies around.
Now, the first of those four companies is out of the bag, with a co-founding team of four academics who have deep biotech experience. Named Eudora, the Replay spoke company will go after three eye diseases: retinitis pigmentosa, Stargardt disease, and Usher syndrome type 1B.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.